Home » Healthcare » Pharmaceuticals » Breast Cancer Treatment Market

Breast Cancer Treatment Market By Drug Type (HER2 Inhibitors, Mitotic Inhibitors, Anti-metabolites, Aromatase Inhibitors, Hormone Receptor Antagonists) – Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 – 2022

Summary
Table Of Content

Market Insights

This report on global breast cancer treatment market studies various drugs used for treatment of breast cancer along with pipeline analysis of upcoming potential drugs. Breast cancer is the second most common cancer observed in women worldwide, accounting for around 17% of all female cancers, making the disease exceptionally prevalent. The predictions shared by GLOBOCON in 2012 suggests that the incidence rate of breast cancer in 2012 was for ages= 65 was 503, 158 and by 2020 it is anticipated that ages=65 will be 643,442. Thus, rising incidences of breast cancer and mounting social awareness in developed and developing countries is assisting the market growth throughout the forecast period.

For the purpose of this study, the various drugs classes studied include HER2 inhibitors, mitotic inhibitors, anti-metabolites, aromatase inhibitors, and hormone receptor. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

The pipeline analysis for breast cancer treatment market comprises projected market sales of Phase III drugs estimated till 2022. The phase III drugs included in the pipeline analysis are Abemaciclib (Eli Lily & Company), Buparlisib (Novartis), NeuVax (Galena Biopharma), Niraparib (Tesaro), Lynparza (AstraZeneca), Veliparib (AbbVie), Neratinib (Puma Biotechnology), Ribociclib (Novartis) and others. The report also covers qualitative information associated with the drugs under phase II and I of the clinical trials.

The geographic segmentation of the global breast cancer treatment market is performed for the regions North America, Europe, Asia Pacific and Rest of the World markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology

Chapter 2 Executive Summary
2.1 Global Breast Cancer Treatment Market Portaiture
2.2 Global Breast Cancer Treatment Market Treament Market, by Drug Class, 2015 (USD Mn)
2.3 Relativity Analysis: Global Breast Cancer Treatment Market, by Geography, 2015 & 2022 (USD Mn)

Chapter 3 Breast Cancer Treatment : Market Dynamics and Outlook
3.1 Breast Cancer Treatment Market Overview
3.2 Breast Cancer Disease Overview and Treatments
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Breast Cancer Treatment Market, 2015 (Value %)

Chapter 4 Global Breast Cancer Treatment Market, By Type of Drug Class
4.1 Preface
4.2 HER2 Inhibitors
4.2.1 Trastuzumab
4.2.2 Pertuzumab
4.2.3 Ado-trastuzumab emtansine
4.2.4 Lapatinib
4.3 Mitotic Inhibitors
4.3.1 Eribulin
4.3.2 Docetaxel
4.3.3 Ixabepilone
4.4 Anti-metabolites
4.4.1 Gemcitabine
4.5 Aromatase Inhibitors
4.5.1 Leterozole
4.5.2 Exemestane
4.5.3 Anastrozole
4.5.4 Palbociclib
4.5.5 Everolimus
4.6 Hormone Receptor Antagonists
4.6.1 Goserelin Acetate
4.6.2 Fulvestrant
4.6.3 Toremifene
4.7 Pipeline Analysis
4.7.1 Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
4.7.1.1 Abemaciclib
4.7.1.2 Buparlisib
4.7.1.3 NeuVax
4.7.1.4 Niraparib
4.7.1.5 Lynparza
4.7.1.6 Veliparib
4.7.1.7 Neratinib
4.7.1.8 Ribociclib
4.7.1.9 Others
4.7.2 Tabular Representation of Phase II and I Drugs

Chapter 5 Global Breast Cancer Treatment Market, By Geography
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia-Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Latin America
5.4.1 Brazil
5.4.2 Mexico
5.4.3 Rest of Latin America
5.6 Middle East and Africa

Chapter 6 Company Profiles
6.1 AstraZeneca plc
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
7.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Eisai Co., Ltd.
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
6.2.4 News Coverage
6.3 Eli Lilly and Company
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Portfolio
6.3.4 News Coverage
6.4 F. Hoffmann-La Roche Ltd.
6.4.1 Business Description
6.4.2 Financial Health and Budget Allocation
6.4.3 Product Portfolio
6.4.4 News Coverage
6.5 GlaxoSmithKline plc
6.5.1 Business Description
6.5.2 Financial Health and Budget Allocation
6.5.3 Product Portfolio
6.5.4 News Coverage
6.6 Novartis International AG
6.6.1 Business Description
6.6.2 Financial Health and Budget Allocation
6.6.3 Product portfolio
6.6.4 News Coverage
6.7 Pfizer, Inc.
6.7.1 Business Description
6.7.2 Financial Health and Budget Allocation
6.7.3 Product Portfolio
6.7.4 News Coverage
6.8 Puma Biotechnology, Inc.
6.8.1 Business Description
6.8.2 Financial Health and Budget Allocation
6.8.3 Product Portfolio
6.8.4 News Coverage
6.9 Sanofi S.A.
6.9.1 Business Description
6.9.2 Financial Health and Budget Allocation
6.9.3 Product Portfolio
6.9.4 News Coverage
6.10 Teva Pharmaceutical Industries Ltd.
6.10.1 Business Description
6.10.2 Financial Health and Budget Allocation
6.10.3 Product Portfolio
6.10.4 News Coverage

List of Figures

FIG. 1 Global Breast Cancer Treatment Market, by Type of Drug Class, 2015 (USD Mn)
FIG. 2 Relativity Analysis: Global Breast Cancer Treatment Market, by Geography, 2015 & 2022 (USD Mn)
FIG. 3 Attractive Investment Proposition, Global Breast Cancer Treatment Market, 2015
FIG. 4 Market Share Analysis: Global Breast Cancer Treatment Market, 2015 (Value %)
FIG. 5 Global Trastuzumab Market, 2013 – 2022 (USD Mn)
FIG. 6 Global Pertuzumab Market, 20137– 2022 (USD Mn)
FIG. 7 Global Ado-trastuzumab Emtansine Market, 2013 –2022 (USD Mn)
FIG. 8 Global Lapatinib Market, 2013 – 2022 (USD Mn)
FIG. 9 Global Eribulin Market, 20137– 2022 (USD Mn)
FIG. 10 Global Docetaxel Market, 2013 –2022 (USD Mn)
FIG. 11 Global Ixabepilone Market, 2013 – 2022 (USD Mn)
FIG. 12 Global Gemcitabine Market, 2013– 2022 (USD Mn)
FIG. 13 Global Leterozole Market, 2013 –2022 (USD Mn)
FIG. 14 Global Exemestane Market, 2013 –2022 (USD Mn)
FIG. 15 Global Anastrozole Market, 2013 –2022 (USD Mn)
FIG. 16 Global Palbociclib Market, 2013 –2022 (USD Mn)
FIG. 17 Global Everolimus Market, 2013 –2022 (USD Mn)
FIG. 18 Pipeline Analysis: Global Abemaciclib Market, Upto 2022 (USD Mn)
FIG. 19 Pipeline Analysis: Global Buparlisib Market, Upto 2022 (USD Mn)
FIG. 20 Pipeline Analysis: Global NeuVax Market, Upto 2022 (USD Mn)
FIG. 21 Pipeline Analysis: Global Niraparib Market , Upto 2022 (USD Mn)
FIG. 22 Pipeline Analysis: Global Lynparza Market, Upto 2022 (USD Mn)
FIG. 23 Pipeline Analysis: Global Veliparib Market, Upto 2022 (USD Mn)
FIG. 24 Pipeline Analysis: Global Neratinib Market, Upto 2022 (USD Mn)
FIG. 25 Pipeline Analysis: Global Ribociclib Market, Upto 2022 (USD Mn)
FIG. 26 Global U.S.Breast Cancer Treatment Market, 2013 – 2022 (USD Mn)
FIG. 27 Global Canada Breast Cancer Treatment Market, 2013 – 2022 (USD Mn)
FIG. 28 Global U.K Breast Cancer Treatment Market, 2013 – 2022 (USD Mn)
FIG. 29 Global Germany Breast Cancer Treatment Market, 2013 – 2022 (USD Mn)
FIG. 30 Global Rest of Europe Breast Cancer Treatment Market, 2013 – 2022 (USD Mn)
FIG. 31 Global China Breast Cancer Treatment Market, 2013 – 2022 (USD Mn)
FIG. 32 Global Japan Breast Cancer Treatment Market, 2013 – 2022 (USD Mn)
FIG. 33 Global Rest of Asia Pacific Breast Cancer Treatment Market, 2013 – 2022 (USD Mn)
FIG. 34 Global Brazil Breast Cancer Treatment Market, 2013 – 2022 (USD Mn)
FIG. 35 Global Mexico Breast Cancer Treatment Market, 2013 – 2022 (USD Mn)
FIG. 36 Global Rest of the Latin America Breast Cancer Treatment Market, 2013 – 2022 (USD Mn)
FIG. 37 Global Middle East and Africa Breast Cancer Treatment Market, 2013 – 2022 (USD Mn)

List of Tables

TABLE 1 Global Breast Cancer Treatment Market, by Type of Drug Class, 2013 – 2022 (USD Mn)
TABLE 2 Global Breast Cancer Treatment Market, by Geography, 2013 – 2022 (USD Mn)
TABLE 3 Global HER 2 Inhibitors Market, 2013 – 2022 (USD Mn)
TABLE 4 Global Mitotic Inhibitors Market, 2013 – 2022 (USD Mn)
TABLE 5 Global Aromatase Inhibitors Market, 2013 – 2022 (USD Mn)
TABLE 6 Global Hormone Receptor Antagonists Market, 2013 – 2022 (USD Mn)
TABLE 7 North America Breast Cancer Treatment Market, by Country, 2013 – 2022 (USD Mn)
TABLE 8 Europe Breast Cancer Treatment Market, by Country, 2013 – 2022 (USD Mn)
TABLE 9 Asia – Pacific Breast Cancer Treatment Market, by Country, 2013 – 2022 (USD Mn)
TABLE 10 Latin America Breast Cancer Treatment Market, by Country, 2013 – 2022 (USD Mn)

Frequently Asked Questions

What is the size of Breast Cancer Treatment Market?

The market for Breast Cancer Treatment is expected to reach US$ XX Mn in 2022.

What is the Breast Cancer Treatment Market CAGR?

The Breast Cancer Treatment market is expected to see significant CAGR growth over the coming years,at 17%.

What is the Forecast period considered for Breast Cancer Treatment Market?

The report is forecasted from 2016-2022.

What is the base year considered for Breast Cancer Treatment Market?

The base year of this report is 2015.

Who are the major players in this Market?

AstraZeneca plc, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, are some of the major players in the global market.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –